Albert Labs Eyes One Dose Psilocybin Treatment for Cancer-related Anxiety
Albert Labs (CSE:ABRT) is gearing up for the first in-human study of its primary drug target, KRN 101, designed as a one dose treatment for cancer-related anxiety and depression, according…